Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Solid Tumors 1Genital Neoplasms, Female 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

pembrolizumab 16Carboplatin 10Paclitaxel 8Nivolumab 7Bevacizumab 6Gemcitabine 4Fulvestrant 4Cisplatin 4olaparib 3lenvatinib 3abemaciclib 3PM 01183 3Oxaliplatin 3Leucovorin 3Letrozole 3Docetaxel 3AZD5305 3tisotumab vedotin 2spartalizumab 2sarilumab 2sargramostim 2sacituzumab govitecan 2ribociclib 2palbociclib 2epacadostat 2enzalutamide 2dostarlimab 2cemiplimab 2anlotinib 2X-Rays 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Endometrial Neoplasms × E-3810 × Clear all
NCT04042116 2022-12-20

A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor

Clovis Oncology, Inc.

Phase 1/2 Suspended
227 enrolled
Gynecologic

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Genital Neoplasms, Female, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡